EOM Pharmaceutical (IMUC) Stock Price, News & Analysis

Company Overview

EOM Pharmaceutical, trading under the ticker OTCMKTS:IMUC, is a clinical-stage biotechnology company focused on the development of cell-based immunotherapies for the treatment of solid tumors. The company leverages dendritic cell technology to create personalized therapeutic vaccines designed to activate a patient’s immune system against tumor-specific antigens. By harnessing key insights into antigen presentation and T-cell activation, EOM Pharmaceutical aims to improve survival outcomes for patients with cancers that currently have limited treatment options.

The company’s lead programs are directed at glioblastoma multiforme and other aggressive tumor types, where standard therapies often fall short. EOM Pharmaceutical’s pipeline candidates undergo a process in which dendritic cells are harvested from patients, exposed to a select panel of tumor antigens, and then reinfused to stimulate a targeted immune response. Early-stage clinical trials have demonstrated the potential for prolonged progression-free survival, and the company continues to refine its manufacturing protocols to enhance product consistency and scalability.

EOM Pharmaceutical maintains collaborative relationships with academic research centers and clinical investigators to support its ongoing trials and preclinical research. The organization’s scientific leadership draws on expertise in immunology, oncology and cell therapy manufacturing. With a commitment to innovation and regulatory compliance, EOM Pharmaceutical is advancing toward later-stage studies and seeks to establish its therapeutic platform as a new standard in personalized cancer care.

Key Stats

• Today's Range: $0.05 to $0.09
• 50-Day Range: $0.04 to $0.10
• 52-Week Range: $0.01 to $0.21
• Volume: 867 shs
• Average Volume: 14,816 shs
• Market Capitalization: $11.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMUC Stock Analysis - Frequently Asked Questions

How have IMUC shares performed this year?

EOM Pharmaceutical's stock was trading at $0.1688 at the beginning of the year. Since then, IMUC shares have decreased by 46.7% and is now trading at $0.0899.

How were EOM Pharmaceutical's earnings last quarter?

EOM Pharmaceutical Holdings, Inc. (OTCMKTS:IMUC) posted its quarterly earnings results on Monday, August, 13th. The company reported ($0.01) EPS for the quarter.

How do I buy shares of EOM Pharmaceutical?

Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of EOM Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that EOM Pharmaceutical investors own include Argos Therapeutics (ARGSQ), Nightfood (NGTF), Meta Platforms (META), LadRx (CYTR), Inovio Pharmaceuticals (INO), MannKind (MNKD) and Agenus (AGEN).

Company Calendar

• Last Earnings: 8/13/2018
• Today: 10/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IMUC
• CIK: 822411
• Web: www.imuc.com
• Phone: (201) 351-0605
• Fax: 818-224-5287
• Employees: 3
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,500,000
• Free Float: 122,354,000
• Market Cap: $11.37 million
• Optionable: Not Optionable
• Beta: 0.05